PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval

Conditions: Gout and Hyperuricemia Interventions: Drug: repaglinide; midazolam; SHR4640; Drug: repaglinide; midazolam; SHR4640; SHR4640 placebo; Drug: repaglinide; midazolam; SHR4640 placebo Sponsors: Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting

https://clinicaltrials.gov/study/NCT06196580

Source: ClinicalTrials.gov - January 9, 2024 Category: Research Source Type: clinical trials

More News: Gout | Research